Ultragenyx Pharmaceutical (RARE) – Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Ultragenyx Pharmaceutical (NASDAQ: RARE):

• 11/12/2024 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $121.00 price target on the stock.
• 11/6/2024 – Ultragenyx Pharmaceutical had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
• 11/6/2024 – Ultragenyx Pharmaceutical had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
• 11/6/2024 – Ultragenyx Pharmaceutical had its price target raised by analysts at Canaccord Genuity Group Inc. from $109.00 to $121.00. They now have a “buy” rating on the stock.
• 11/6/2024 – Ultragenyx Pharmaceutical had its price target raised by analysts at HC Wainwright from $82.00 to $95.00. They now have a “buy” rating on the stock.
• 10/22/2024 – Ultragenyx Pharmaceutical had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
• 10/21/2024 – Ultragenyx Pharmaceutical had its price target raised by analysts at TD Cowen from $61.00 to $73.00. They now have a “buy” rating on the stock.
• 10/1/2024 – Ultragenyx Pharmaceutical had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
• 9/26/2024 – Ultragenyx Pharmaceutical had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE opened at $46.40 on Thursday. Ultragenyx Pharmaceutical Inc. has a 52 week low of $37.02 and a 52 week high of $60.37. The stock has a 50 day moving average price of $53.80 and a two-hundred day moving average price of $48.39. The firm has a market capitalization of $4.28 billion, a P/E ratio of -7.17 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The business had revenue of $139.49 million for the quarter, compared to analysts’ expectations of $135.28 million. During the same period last year, the business earned ($2.23) EPS. The business’s revenue was up 42.3% on a year-over-year basis. On average, equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.21 earnings per share for the current year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total value of $1,117,000.00. Following the sale, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at approximately $124,209,562.25. The trade was a 0.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Howard Horn sold 7,465 shares of the stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the transaction, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at $4,869,800.76. This represents a 7.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,556 shares of company stock valued at $1,515,967. Corporate insiders own 5.80% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Ultragenyx Pharmaceutical by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 8,700,007 shares of the biopharmaceutical company’s stock worth $406,203,000 after acquiring an additional 26,575 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Ultragenyx Pharmaceutical by 3.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,568,873 shares of the biopharmaceutical company’s stock valued at $166,632,000 after purchasing an additional 120,175 shares during the period. Alkeon Capital Management LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 34.3% during the 3rd quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company’s stock valued at $167,301,000 after buying an additional 769,884 shares in the last quarter. Federated Hermes Inc. boosted its holdings in Ultragenyx Pharmaceutical by 8.7% in the 2nd quarter. Federated Hermes Inc. now owns 2,107,025 shares of the biopharmaceutical company’s stock worth $86,599,000 after buying an additional 168,345 shares during the period. Finally, Millennium Management LLC grew its stake in Ultragenyx Pharmaceutical by 103.8% in the 2nd quarter. Millennium Management LLC now owns 1,850,734 shares of the biopharmaceutical company’s stock valued at $76,065,000 after buying an additional 942,529 shares in the last quarter. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.